Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.
复制标题
DOI：
10.1155/2016/1752854
复制
发表时间：
2016
影响因子：
--
通讯作者：
Fabris B
中科院分区：
文献类型：
--
作者：
Bernardi S;Bossi F;Toffoli B;Fabris B
心血管疾病（CVD）仍然是西方社会死亡和过早残疾的主要原因。评估CVD的风险是临床决策的一个重要方面。骨保护素（osteoprotegerin，OPG）及其配体，即核因子κB受体激活因子配体（receptor activator of nuclear factor κB ligand，RANKL）和肿瘤坏死因子相关凋亡诱导配体（TNF-related aptosis-inducing ligand，TNF-α）已成为近年来研究的热点。基于现有的文献和我们在这一领域的经验，在这里我们回顾OPG和TRAIL在CVD中的可能作用及其作为CVD生物标志物的潜在效用。
Cardiovascular diseases (CVD) remain the major cause of death and premature disability in Western societies. Assessing the risk of CVD is an important aspect in clinical decision-making. Among the growing number of molecules that are studied for their potential utility as CVD biomarkers, a lot of attention has been focused on osteoprotegerin (OPG) and its ligands, which are receptor activator of nuclear factor κB ligand (RANKL) and TNF-related apoptosis-inducing ligand. Based on the existing literature and on our experience in this field, here we review what the possible roles of OPG and TRAIL in CVD are and their potential utility as CVD biomarkers.